This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's (MRK) Two Keytruda sBLAs Get Accepted by the FDA
by Zacks Equity Research
FDA likely to decide on Merck's (MRK) sBLA for Keytruda as an adjuvant therapy in certain patients with RCC on Dec 10 and in certain patients with MSI-H/dMMR advanced endometrial carcinoma on Mar 28, 2022.
Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance
by Zacks Equity Research
Halozyme (HALO) second-quarter earnings and sales beat estimates. The company raises 2021 guidance. Stock up.
Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track
by Zacks Equity Research
Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.
Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) reports mixed second-quarter results and ttightens 2021 sales forecast. Stock down in pre-market trading.
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
by Zacks Equity Research
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Glaxo (GSK) Beats Earnings and Revenues Estimates in Q2
by Zacks Equity Research
Glaxo (GSK) beats earnings as well as revenues estimates in the second quarter of 2021. Stock up.
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
by Zacks Equity Research
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
by Zacks Equity Research
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
Lilly (LLY) Stock Riding on Pipeline Developments This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda
by Zacks Equity Research
Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.